Lab guide · Comparisons
BPC-157 vs TB-500: Structure, Pathways and Research Differences
BPC-157 vs TB-500 compares two unrelated peptides that are often mentioned together: a 15-residue peptide described as part of a gastric-juice protein, and thymosin beta-4, a 43-residue actin-binding protein (sold under the TB-500 name). This guide sets out the seven differences that matter, what the evidence for each looks like and why the two should not be treated as interchangeable.
Key takeaways
- BPC-157 is a synthetic 15-residue peptide (about 1419.5 g/mol); TB-500, as supplied by Baltic Peptides, is full-length 43-residue thymosin beta-4 (about 4963.5 g/mol).
- Their best-characterised research pathways differ: VEGFR2-Akt-eNOS signalling in endothelial cell studies for BPC-157, and G-actin sequestration plus ILK-Akt signalling for thymosin beta-4.
- Both are studied mainly in cell and animal injury models, and neither has an approved human indication.
- The name TB-500 is also used for a seven-residue fragment, so the molecule must be confirmed by mass before any comparison is meaningful.
BPC-157 vs TB-500 at a glance
The two peptides are often grouped because both are studied in tissue-injury models, but they differ in almost every chemical and biological respect. The table gives seven differences.
| # | Feature | BPC-157 | TB-500 (thymosin beta-4) |
|---|---|---|---|
| 1 | Sequence and size | 15 residues, GEPPPGKPADDAGLV | 43 residues, N-acetylated; the name is also used for a 7-residue fragment |
| 2 | Origin | Described as a partial sequence of a gastric-juice protein | A thymosin found in most cells, first isolated from thymus preparations |
| 3 | Formula and mass | C62H98N16O22, 1419.5 g/mol, CAS 137525-51-0 | C212H350N56O78S, 4963.5 g/mol, CAS 77591-33-4 |
| 4 | Best-characterised pathway | VEGFR2-Akt-eNOS in endothelial cells | 1:1 binding to G-actin; ILK-Akt signalling in cardiac cells |
| 5 | Main preclinical areas | Tendon, ligament, muscle, gastrointestinal and vascular models | Dermal, corneal and cardiac models, and cell migration |
| 6 | Human evidence | One retrospective report of 12 patients; no human safety data | Trials of thymosin beta-4 run or proposed; none has led to approval |
| 7 | Regulatory notes | No approved indication; listed in the 2025 review as FDA Category 2 (2023) with a WADA prohibition | No approved indication; thymosin-beta-4 and derivatives such as TB-500 are named in WADA section S2 |
Research use only. This comparison summarises published laboratory and animal research. Baltic Peptides supplies both compounds for in-vitro and preclinical research by qualified researchers; neither is a medicine and neither is for human or veterinary use.
Chemistry: a peptide versus a small protein
The first difference is scale. BPC-157 is a linear 15-residue peptide with no cysteine, methionine or tryptophan, so it is chemically robust. Thymosin beta-4 is nearly three times longer, carries one oxidation-prone methionine and is N-terminally acetylated. The formula, mass and CAS number for each match the PubChem records, as described in What is BPC-157 and What is TB-500. Because the masses differ by more than 3,500 Da, intact-mass testing separates them immediately.
Origin and research history
BPC-157 (Body Protection Compound-157) was first described in 1992, according to the systematic review by Vasireddi et al. (2025), and the literature spans studies from 1993 to 2024. Thymosin beta-4 belongs to the thymosin family, named for the thymus preparations from which it was first isolated, and its later tissue-repair studies are reviewed by Goldstein and Kleinman (2015).
The two come from unrelated research traditions: gastric cytoprotection for BPC-157 and thymic and actin biology for thymosin beta-4.
Pathways studied
For BPC-157, Hsieh et al. (2017) reported that it promoted angiogenesis in the chick chorioallantoic membrane and tube-formation assays and activated VEGFR2-Akt-eNOS signalling in a time-dependent way. No single dedicated receptor is established.
For thymosin beta-4, the best-established property is binding to monomeric G-actin in a 1:1 complex, as reviewed by Goldstein et al. (2005), with additional ILK-Akt signalling reported in cardiac cell studies.
What the evidence looks like for each
| Evidence type | BPC-157 | Thymosin beta-4 / TB-500 |
|---|---|---|
| Cell studies | Endothelial signalling; tendon fibroblast migration and survival | Cell migration and survival; actin dynamics |
| Animal studies | Rat tendon, muscle, ligament and gastrointestinal models | Mouse and rodent cardiac, dermal and corneal models |
| Human studies | A single retrospective report in 12 patients | Trials of the full-length protein; not transferable to the fragment |
| Independence | Several animal papers share authors | Broader, older literature with multiple groups |
The TB-500 naming problem
TB-500 is used for full-length thymosin beta-4 by some suppliers and for a seven-residue fragment, Ac-LKKTETQ, by others. Most mechanistic findings concern the full-length protein, so a comparison with BPC-157 is only meaningful once the molecule has been confirmed by mass. A fuller treatment is in TB-500 vs thymosin beta-4.
What about the BPC-157 and TB-500 blend?
A blend is a physical mixture, so each component keeps its own properties, and the evidence for each does not establish how the mixture behaves. Whether the two act additively, synergistically or antagonistically has to be measured against single-compound controls. See peptide blends explained.
Limits of this comparison
- Almost all evidence for both is preclinical, so the comparison describes models, not outcomes in people.
- Differences in model, outcome measure and author group make direct head-to-head comparison across papers unreliable.
- No direct comparison of the two in the same experiment was found in the sources reviewed.
- Regulatory and anti-doping statuses can change.
Sources and further reading
- Vasireddi N. et al. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J 21(4):485-495. PubMed
- Hsieh M.J. et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med 95:323-333. PubMed
- Goldstein A.L. and Kleinman H.K. (2015). Advances in the basic and clinical applications of thymosin beta-4. PubMed
- Goldstein A.L. et al. (2005). Thymosin beta-4: actin-sequestering protein moonlights to repair injured tissues. PubMed
- WADA Prohibited List, section S2. WADA
All Baltic Peptides products are supplied strictly for laboratory research use. They are not medicines, supplements or food and are not for human or animal use. This article explains analytical and chemical concepts and is for educational purposes only.
FAQ
Common questions
What is the difference between BPC-157 and TB-500?
How do the molecular weights of BPC-157 and TB-500 compare?
Do BPC-157 and TB-500 work the same way?
Are BPC-157 and TB-500 studied in the same models?
Is TB-500 the same as thymosin beta-4?
Is there human evidence for either compound?
Is a BPC-157 and TB-500 blend the same as using each separately?
Keep reading
Related reading
What is BPC-157?
Structure, history and the evidence behind BPC-157.
What is TB-500?
Thymosin beta-4 and the TB-500 naming problem.
Peptide blends explained
Why component research does not define a mixture.
Research-grade BPC-157 and TB-500, tested before they ship
Independent HPLC and mass spec results for every batch, dispatched from the EU.
